Filgrastine (filgrastim biosimilar) / Blausiegel Industry and Trade - LARVOL DELTA

Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: Blau Farmaceutica S.A.

New P3 trial • Breast Cancer • Oncology • Solid Tumor

[VIRTUAL] CASE REPORT: INVASIVE ASPERGILOSIS AND COVID-19 IN A PATIENT WITH MYELODYSPLASIA (HEMO 2020) - "He evolved with the need for mechanical ventilation for six days, made use of several antimicrobial therapeutic regimens, including Oseltamivir, Ivermectin, Vancomycin, Meropenem and Polymyxin B, but he had a persistent fever. A tracheal aspirate culture was performed, which showed the presence of Aspergillus fumigatus, and Voriconazole was started... Intensive care and early diagnosis are essential to provide a favorable outcome to the numerous clinical complications of hematological diseases."

Clinical • Critical care • Hematological Disorders • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia